A Randomized Phase III trial of Paclitaxel plus Cisplatin versus Paclitaxel plus Carboplatin in Stage IVB, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)

INTERVENTION: A: chemotherapy:Paclitaxel/Cisplatin B: chemotherapy:Paclitaxel/Carboplatin CONDITION: uterine cervical neoplasms PRIMARY OUTCOME: overall survival SECONDARY OUTCOME: progression‐free survival, response rate, adverse events, severe adverse events, proportion of periods of non‐hospitalization to those of the planned treatment INCLUSION CRITERIA: 1) histologically proven uterine cervical cancer 2) squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the uterine cervix 3) one of the followings, 1.primary stage IVb cervical cancer 2.the first relapse or persistent cervical cancer after curative first line treatments 3.the second relapse or persistent cervical cancer after curative second line treatmets including radiation, systemic chemotherapy, hormonal therapy, or vaccination therapy for the first relapse 4) Patients may have been previously treated with less than 50 Gy of palliative radiation therapy 5) Patients have received no prior treatment or a certain interval must have elapsed from the last administration of previous treatments including palliative radiatinon therapy 6) one of the followings, 1.There is at least one metastatic lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN 2.There is no metastatic lesion outside the pelvic